CONCORDBIO — Concord Biotech Balance Sheet
0.000.00%
HealthcareMid Cap
- IN₹173.98bn
- IN₹170.97bn
- IN₹10.17bn
Annual balance sheet for Concord Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,008 | 2,019 | 1,628 | 1,804 | 2,817 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,113 | 2,311 | 2,602 | 3,231 | 3,789 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 5,386 | 6,071 | 6,327 | 7,277 | 8,962 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3,809 | 5,577 | 6,436 | 7,655 | 7,865 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 9,405 | 11,825 | 13,128 | 15,140 | 17,007 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,151 | 1,057 | 1,552 | 1,918 | 1,422 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,703 | 1,832 | 2,096 | 2,240 | 1,741 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 7,702 | 9,994 | 11,032 | 12,900 | 15,266 |
Total Liabilities & Shareholders' Equity | 9,405 | 11,825 | 13,128 | 15,140 | 17,007 |
Total Common Shares Outstanding |